Taken together, these data support the hypothesis that TRPC4/C5 represent novel and safe non-opioid targets for the treatment of several pain conditions, in addition to attenuating suffering, depression, and anxiety associated with chronic pain. The gene discussed is TRPC4; the disease is depressive symptom measurement.